MKI67 and pancreatic neuroendocrine tumor: The 3 patients with multimodal highly individualized treatment in the group “other” showed an exceptionally long time to progression: the first patient with a pancreatic NET G3, Ki67 25%, was diagnosed at the age of 14 and received a combination therapy of temozolomide and thalidomide, followed by intraarterial PRRT and maintenance treatment with sunitinib, and she progressed after 81.9 months with new brain metastases.